Wen et al. Trials (2016) 17:357 DOI 10.1186/s13063-016-1500-4
ERRATUM
Open Access
Erratum to: 'Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial' Ze-Huai Wen1,2, Mei-Ling Xuan1, Yu-Hong Yan3, Xiao-Yan Li1, Dan-Ni Yao3, Geng Li1, Xin-Feng Guo1, Ai-Hua Ou1 and Chuan-Jian Lu3* Erratum Unfortunately, the original version of this article [1] contained an error. The superiority margin difference should be 5 % instead of 10 %. We performed a superiority test of two independent proportions with superiority margin difference of 5 % by PASS 11.0 software again, and the results were the same as mentioned in the paper before. The sentence in the "Sample size calculation" part (Page 5) is corrected as follows: According to the supposition and as calculated by PASS 11.0 software (NCSS, LLC, Kaysville, Utah, USA), sample size of 239 in each group can achieve 90 % power and to rule out a two-sided type I error of 5 % to detect a superiority margin difference of 5 % in this two-arm trial with equal allocation in each group. Author details 1 Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China. 2 National Centre for Design Measurement and Evaluation in Clinical Research, Guangzhou University of Chinese Medicine, 12 Jichang Road, Guangzhou 510405, China. 3Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China. Received: 12 July 2016 Accepted: 12 July 2016
Submit your next manuscript to BioMed Central and we will help you at every step: • We accept pre-submission inquiries • Our selector tool helps you to find the most relevant journal
Reference 1. Wen Z-H, Xuan M-L, Yan Y-H, Li X-Y, Yao D-N, Li G, Guo X-F, Ou A-H, Lu C-J. Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial. Trials. 2014;15:294. * Correspondence: [email protected] 3 Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China Full list of author information is available at the end of the article
• We provide round the clock customer support • Convenient online submission • Thorough peer review • Inclusion in PubMed and all major indexing services • Maximum visibility for your research Submit your manuscript at www.biomedcentral.com/submit
© 2016 Wen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
ERRATUM
Open Access
Erratum to: 'Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial' Ze-Huai Wen1,2, Mei-Ling Xuan1, Yu-Hong Yan3, Xiao-Yan Li1, Dan-Ni Yao3, Geng Li1, Xin-Feng Guo1, Ai-Hua Ou1 and Chuan-Jian Lu3* Erratum Unfortunately, the original version of this article [1] contained an error. The superiority margin difference should be 5 % instead of 10 %. We performed a superiority test of two independent proportions with superiority margin difference of 5 % by PASS 11.0 software again, and the results were the same as mentioned in the paper before. The sentence in the "Sample size calculation" part (Page 5) is corrected as follows: According to the supposition and as calculated by PASS 11.0 software (NCSS, LLC, Kaysville, Utah, USA), sample size of 239 in each group can achieve 90 % power and to rule out a two-sided type I error of 5 % to detect a superiority margin difference of 5 % in this two-arm trial with equal allocation in each group. Author details 1 Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China. 2 National Centre for Design Measurement and Evaluation in Clinical Research, Guangzhou University of Chinese Medicine, 12 Jichang Road, Guangzhou 510405, China. 3Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China. Received: 12 July 2016 Accepted: 12 July 2016
Submit your next manuscript to BioMed Central and we will help you at every step: • We accept pre-submission inquiries • Our selector tool helps you to find the most relevant journal
Reference 1. Wen Z-H, Xuan M-L, Yan Y-H, Li X-Y, Yao D-N, Li G, Guo X-F, Ou A-H, Lu C-J. Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial. Trials. 2014;15:294. * Correspondence: [email protected] 3 Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China Full list of author information is available at the end of the article
• We provide round the clock customer support • Convenient online submission • Thorough peer review • Inclusion in PubMed and all major indexing services • Maximum visibility for your research Submit your manuscript at www.biomedcentral.com/submit
© 2016 Wen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
